Skip to main content

memo - Magazine of European Medical Oncology OnlineFirst articles

Open Access 23.02.2024 | case report

Seminal vesicle metastasis from transverse colon adenocarcinoma: a unique case report

Seminal vesicle metastasis from colon adenocarcinoma is very rare, with only two case reports in the literature [ 1 , 2 ]. We report a case of colon adenocarcinoma metastatic to the seminal vesicles discovered 6 years after the initial diagnosis …

verfasst von:
Juliana Arenas Hoyos, Julian Serrano Giraldo, Andres Felipe Gutierrez Rojas

09.02.2024 | original report

β-adrenergic modulation of IL-6/gp130 and SOCS-1 in multiple myeloma: therapeutic strategy for stress induced-inflammatory response

Multiple Myeloma (MM) is characterized as an incurable, biologically heterogeneous disease of the plasma cells. It is defined by uncontrolled proliferation of monoclonal plasma cells in the bone marrow [ 1 ]. Bone marrow stromal cells (BMSC) are …

verfasst von:
Raika Naiebi, Saeid Abroun, Ph. D., Amir Atashi, Leila Shafiee, Mohammadarian Akbari, Mohammad Hasan Maleki, Morvarid Siri, M. Sc.

Open Access 08.02.2024 | short review

Rare oncogenic alterations in NSCLC—focus on atypical EGFR mutations

Invited short review

In non-small cell lung cancer (NSCLC), mutations within the epidermal growth factor receptor (EGFR) gene are very common driver mutations. EGFR tyrosine kinase inhibitors (TKIs), have shown remarkable efficacy in patients with common classical …

verfasst von:
Yana Sharapova, PhD, Sonja Loges, MD, PhD, Melanie Janning, MD

26.01.2024 | original report

Can artificial intelligence provide accurate and reliable answers to cancer patients’ questions about cancer pain? Comparison of chatbots based on ESMO cancer pain guideline

Pain management is a significant concern for cancer patients. Even in patients undergoing curative treatment, cancer pain can be severe. Because chemotherapy-induced neuropathic pain can persist even after treatment, searching for information …

verfasst von:
Kadriye Bir Yücel, MD, Osman Sutcuoglu, MD, Ozan Yazıcı, MD, Ahmet Ozet, MD, Nuriye Ozdemir, MD

Open Access 25.01.2024 | short review

Antibody–drug conjugates in ovarian cancer

Ovarian cancer (OC) management presents a challenging scenario in clinical practice due to its late diagnosis, high recurrence rate, and dismal 5‑year survival rate of 45%—especially in platinum-resistant cases. Antibody–drug conjugates (ADCs) are …

verfasst von:
Barin Feroz, Christian Marth, Alain Gustave Zeimet

Open Access 11.01.2024 | short review

Pulmonary puzzles: salivary gland-type tumors of the lung and their metastatic equivalents

In the last decade, the understanding of lung neoplasms, particularly rare salivary gland-type tumors (SGT), has deepened significantly. This review intends to spotlight the latest findings, particularly emphasizing the differentiation between …

verfasst von:
Gheorghe-Emilian Olteanu, Luka Brcic

08.01.2024 | case report

Transformation of epidermal growth factor receptor-mutated non-small cell lung cancer into small cell lung cancer—case report

Epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) generally has a favorable prognosis when compared to lung cancer without this alteration due to the advent of EGFR tyrosine kinase inhibitors (TKI). However, during …

verfasst von:
Nino Rafael Müser, Klaus Kirchbacher, Georg-Christian Funk

Open Access 29.12.2023 | short review

Upper-GI highlights from ASCO and ASCO-GI 2023 meetings: changing paradigm in treatment sequence

The annual meeting of the American Society of Medical Oncology (ASCO) was held as usual in Chicago, while the meeting focused on gastrointestinal tumors, ASCO-GI, was held in San Francisco. In particular, ASCO-GI included many phase III trials …

verfasst von:
Aysegül Ilhan-Mutlu, MD, PhD, Elisabeth Sophie Bergen, MD, PhD

Open Access 18.12.2023 | short review

Diagnosis and management of mediastinal extragonadal germ cell tumors

Extragonadal germ cell tumors (EGCT) are rare and comprise only 2–3% of all testicular germ cell tumors. The majority of EGCT are located in the mediastinum, followed by the retroperitoneum. Although histologically similar to germ cell tumors …

verfasst von:
Prof. Dr. med. Axel Heidenreich, Pia Paffenholz, David Pfister

Open Access 05.12.2023 | short review

ASCO 2023: highlights in breast cancer

The 2023 annual meeting of the American Society of Clinical Oncology (ASCO) was again held in June 2023 in Chicago. While not immediately practice changing, results from several interesting studies in the field of breast cancer (BC) were reported.

verfasst von:
Rupert Bartsch

Open Access 05.12.2023 | short review

Emerging treatment strategies in chronic B-cell malignancies—News from ICML 2023

Implementation of targeted drugs in the treatment landscape of indolent B‑cell malignancies has facilitated long-term remissions and reduced treatment-related toxicities for a substantial proportion of patients across several disease entities.

verfasst von:
Jan-Paul Bohn, MD, PhD

20.11.2023 | original report

Decitabine combined with low-dose cytarabine, aclarubicin and rhG-CSF regimen may be a potential alternative for relapsed/refractory acute myeloid leukemia: A single-center study

Acute myeloid leukemia (AML) is a highly heterogeneous malignant disorder characterized by the aberrant clonal proliferation of hematopoietic stem or progenitor cells. Approximately 60–80% of adult patients with AML achieve complete remission (CR) …

verfasst von:
Yu Fu, Long Su, Yuying Li, Yehui Tan

17.10.2023 | original report

Prognostic factors of long-term survivors with unresectable pancreatic cancer: a retrospective analysis

Despite the increasing number of patients with metastatic pancreatic adenocarcinoma (mPDAC) receiving second-line chemotherapy, little data have been reported about long-term survivors of mPDAC and prognostic factors. The study analyzes the …

verfasst von:
Dr. Giuseppe A. Colloca, Antonella Venturino

Open Access 31.08.2023 | short review

Brief update on systemic therapies in myeloproliferative neoplasms

Over the past years we have gained considerable insights into the biology and consequent therapeutic options in myeloproliferative neoplasms. In this review we aim to highlight the most relevant recent developments in this field with special focus …

verfasst von:
Janine Steichen, MD, Dominik Wolf